Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $1,076,412.32 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 268,432 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the sale, the chief financial officer now directly owns 1,032,754 shares in the company, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Checkpoint Therapeutics Stock Performance

CKPT stock traded up $0.38 during trading on Friday, reaching $3.75. The company had a trading volume of 2,234,921 shares, compared to its average volume of 675,598. Checkpoint Therapeutics, Inc. has a twelve month low of $1.38 and a twelve month high of $4.50. The company has a market cap of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34. The firm has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $2.70.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Sell-side analysts expect that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

CKPT has been the subject of several recent analyst reports. Lake Street Capital raised their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday.

Institutional Trading of Checkpoint Therapeutics

Several large investors have recently added to or reduced their stakes in CKPT. Virtu Financial LLC acquired a new stake in shares of Checkpoint Therapeutics in the third quarter worth $30,000. XTX Topco Ltd acquired a new position in Checkpoint Therapeutics during the second quarter valued at $34,000. Gladstone Institutional Advisory LLC boosted its holdings in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after purchasing an additional 20,500 shares during the last quarter. Magnus Financial Group LLC grew its position in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 4,000 shares during the period. Finally, Choreo LLC raised its stake in shares of Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after buying an additional 7,080 shares during the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.